RT Journal Article
SR Electronic
T1 Innate lymphoid cell composition associates with COVID-19 disease severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.13.20211367
DO 10.1101/2020.10.13.20211367
A1 García, Marina
A1 Kokkinou, Efthymia
A1 García, Anna Carrasco
A1 Parrot, Tiphaine
A1 Palma Medina, Laura M.
A1 Maleki, Kimia T.
A1 Christ, Wanda
A1 Varnaitė, Renata
A1 Filipovic, Iva
A1 Ljunggren, Hans-Gustaf
A1 Björkström, Niklas K.
A1 Folkesson, Elin
A1 Rooyackers, Olav
A1 Eriksson, Lars I.
A1 Sönnerborg, Anders
A1 Aleman, Soo
A1 Strålin, Kristoffer
A1 Gredmark-Russ, Sara
A1 Klingström, Jonas
A1 Mjösberg, Jenny
A1 the Karolinska KI/K COVID-19 Study Group
YR 2020
UL http://medrxiv.org/content/early/2020/10/14/2020.10.13.20211367.abstract
AB Objectives The role of innate lymphoid cells (ILCs) in coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unknown. Understanding the immune response in COVID-19 could contribute to unravel the pathogenesis and identification of treatment targets. To describe the phenotypic landscape of circulating ILCs in COVID-19 patients and to identify ILC phenotypes correlated to serum biomarkers, clinical markers, and laboratory parameters relevant in COVID-19.Methods Blood samples collected from moderately (n=11) and severely ill (n=12) COVID-19 patients as well as healthy control donors (n=16), were analyzed with 18-parameter flow cytometry. Using supervised and unsupervised approaches, we examined the ILC activation status and homing profile. Clinical and laboratory parameters were obtained from all COVID-19 patients and serum biomarkers were analyzed with multiplex immunoassays.Results ILCs were largely depleted from the circulation of COVID-19 patients compared with healthy controls. Remaining circulating ILCs from patients revealed increased frequencies of ILC2 in moderate COVID-19, with a concomitant decrease of ILC precursors (ILCp), as compared with controls. ILC2 and ILCp showed an activated phenotype with increased CD69 expression, whereas expression levels of the chemokine receptors CXCR3 and CCR4 were significantly altered in ILC2 and ILCp, and ILC1, respectively. The activated ILC profile of COVID-19 patients was associated with soluble inflammatory markers, while frequencies of ILC subsets were correlated with laboratory parameters that reflect the disease severity.Conclusion This study provides insights into the potential role of ILCs in immune responses against SARS-CoV-2, particularly linked to the severity of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Knut and Alice Wallenberg Foundation, Nordstjernan AB, Swedish Research Council Vetenskapsradet (VR), Karolinska Institutet and the SciLifeLab COVID-19 National Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Swedish Ethical Review Authority and conducted according to the Declaration of Helsinki. All necessary patient/participant informed consent has been obtained and the appropriate institutional forms have been archivedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCurated flow cytometry data is available for exploration via the Karolinska COVID-19 Immune Atlas (homepage currently under construction). Other data are available upon request to the corresponding author.